Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64  years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial

CONCLUSIONS: Tri Fluvac was well tolerated, and immunogenicity was non-inferior to the active comparator, meeting U.S. Food and Drug Administration (FDA) criteria for adult vaccine licensure. Few acute respiratory infections were reported during intense COVID-19 pandemic restrictions, resulting in insufficient power to evaluate clinical efficacy.PMID:38042698 | DOI:10.1016/j.vaccine.2023.11.050

Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Kriengkrai Prasert Prabda Praphasiri Hatairat Lerdsamran Sutthichai Nakphook Darunee Ditsungnoen Sutthinan Chawalchitiporn Kanlaya Sornwong Kittisak Poopipatpol Ponthip Wirachwong Piengthong Narakorn Somchaiya Surichan Nava Suthepakul Napawan Thangsupanim Source Type: research